Skip to main content

Table 2 Characteristics of the whole study population

From: Contrast-enhanced spectral mammography: successful initial clinical institute experience

Variable   N %
Age category ≤ 40 years 44 35.8%
> 40 years 79 64.2%
ACR grade Grade A 4 3.3%
Grade B 45 36.6%
Grade C 68 55.3%
Grade D 6 4.9%
Number of lesions by SMG Nil 6 4.9%
Single lesion 96 78.0%
2 lesions 12 9.8%
3 lesions 5 4.1%
4 lesions 4 3.3%
BIRADS class by SMG BIRADS1 7 5.7%
BIRADS 2 0 0.0%
BIRADS 3 23 18.7%
BIRADS 4 40 32.5%
BIRADS 5 4 3.3%
BIRADS 6 49 39.8%
Indication for CESM Follow-up of neo-adjuvant chemotherapy 25 20.3%
Mass in dense breast 8 6.5%
Staging of breast cancer 23 18.7%
Suspicious lesion on mammography with no US correlate 17 13.8%
Focal asymmetry 24 19.5%
Postoperative follow-up 12 9.8%
Parenchymal distortion 13 10.6%
Suspicious palpable lesion 1 0.8%
Number of lesions by CESM Nil 22 17.9%
Single lesion 61 49.6%
2 lesions 12 9.8%
3 lesions 22 17.9%
4 lesions 5 4.1%
5 lesions 1 0.8%
Grade of enhancement No enhancement 24 19.5%
Minimal 12 9.8%
Mild 11 8.9%
Moderate 14 11.4%
Marked 62 50.4%
BIRADS class by CESM BIRADS 2 29 23.6%
BIRADS 3 2 1.6%
BIRADS 4 37 30.1%
BIRADS 5 8 6.5%
BIRADS 6 47 38.2%
Pathological type and course Adenosis 3 2.4%
Atypical ductal hyperplasia 3 2.4%
Benign postoperative changes 5 4.1%
Complete response 8 6.5%
Cyst 4 3.3%
DCIS 11 8.9%
Fat necrosis 3 2.4%
Fibroadenoma 5 4.1%
Fibrocystic changes 3 2.4%
Granulomatous mastitis 4 3.3%
Hamartoma 1 0.8%
IDC 18 14.6%
IDC within in-situ component 11 8.9%
ILC 13 10.6%
IMLN 2 1.6%
Infected cyst 1 0.8%
Lipoma 1 0.8%
Minimal residual disease 5 4.1%
Mucinous carcinoma 2 1.6%
Papilloma 2 1.6%
Partial response 2 1.6%
Recurrent IDC 4 3.3%
Stationary disease 12 9.8%
Reference index Follow-up 13 10.6%
Needle aspiration 5 4.1%
Tru-Cut biopsy 55 44.7%
Surgical biopsy 49 39.8%
Stereotactic biopsy 1 0.8%
Final diagnosis Benign 37 30.1%
Malignant 86 69.9%
  1. Data are number (N) and percentage (%)